Stock PRCT PROCEPT BIOROBOTICS CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Ratings PROCEPT BioRobotics Corporation

Equities

PRCT

US74276L1052

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-04-26 EDT 		5-day change 1st Jan Change
51.83 USD -0.86% Intraday chart for PROCEPT BioRobotics Corporation +3.27% +23.67%
03-21 Procept Biorobotics Insider Sold Shares Worth $263,243, According to a Recent SEC Filing MT
03-08 Procept Biorobotics Insider Sold Shares Worth $428,384, According to a Recent SEC Filing MT

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.
  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
  • Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
  • Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

Weaknesses

  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • Low profitability weakens the company.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
PROCEPT BIOROBOTICS CORPORATION Stock PROCEPT BioRobotics Corporation
+23.67% 2.66B -
ABBOTT LABORATORIES Stock Abbott Laboratories
-2.31% 187B
C+
MEDTRONIC PLC Stock Medtronic plc
-3.20% 106B
C
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-5.04% 66.9B
A
DEXCOM, INC. Stock DexCom, Inc.
+0.20% 49.45B
B-
CENCORA, INC. Stock Cencora, Inc.
+17.29% 48B
B-
HOYA CORPORATION Stock Hoya Corporation
+4.06% 40.84B
B+
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+2.07% 26.48B
B
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
+2.36% 26.25B
A-
TERUMO CORPORATION Stock Terumo Corporation
+12.96% 24.62B
A-
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. PRCT Stock
  4. Ratings PROCEPT BioRobotics Corporation